Text Size: A A A

MEDIA CONTACTS

Alice Izzo
Vice President, Corporate Affairs
858.642.7272
alice.izzo@amylin.com
Anne Erickson
Sr. Director, Corporate Affairs
858.754.4443
anne.erickson@amylin.com

PRESS RELEASES

The information in these news pages is accurate or current only as of the date of the particular press release or posting. Amylin does not update press releases once they have been made public. Press releases may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties.

DATE	TITLE
02/25/10	Exenatide Once Weekly New Drug Application Review Extended By FDA Due to Weather-Related Closure
02/22/10	Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
01/27/10	Amylin Pharmaceuticals Reports 2009 Financial Results
01/20/10	Amylin Pharmaceuticals to Webcast Year-End Financial Results
01/11/10	Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
01/04/10	Amylin Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
12/15/09	Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
12/08/09	Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
11/05/09	Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
11/02/09	Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update

More Press Releases

MEDIA CONTACTS

PRESS RELEASES

02/25/10

02/22/10

01/27/10

01/20/10

01/11/10

01/04/10

12/15/09

12/08/09

11/05/09

11/02/09